Kunal Shah, MD
Endocrinology, Diabetes & Metabolism · Princeton, NJNPI 1962881516
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $309 of the $435 with a category attached, or 71.0%. Medtronic accounts for 65.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $283 and has fallen 90.9% since, to $26 in 2022. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NJ, where the typical reported total is $1,953.
Across 8 payments — averaging $54.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$283
- Novo Nordisk$88
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$38
- Abbott$26
Across 5 payments — averaging $42,918 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$215K
What the payments were for
- Food & beverage$30971%
- Education$12629%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 4 | $283 |
| Novo Nordisk | 1 | $88 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $38 |
| Abbott | 1 | $26 |
How this compares
$435 in reported general payments places this provider in the 20th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 218 | $261,938 |
| TrulicityDulaglutide | 97 | $105,702 |
| MounjaroTirzepatide | 69 | $75,391 |
| JardianceEmpagliflozin | 87 | $70,734 |
| FarxigaDapagliflozin Propanediol | 28 | $24,090 |
| SynjardyEmpagliflozin/Metformin Hcl | 17 | $16,733 |
| WegovySemaglutide | 12 | $16,270 |
| JanuviaSitagliptin Phosphate | 23 | $15,158 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 26 | $13,831 |
| Repatha SureclickEvolocumab | 17 | $11,652 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $8,975 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $7,523 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $7,482 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $6,160 |
| Humalog Kwikpen U-100Insulin Lispro | 20 | $4,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $88 | $278,208230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Princeton
- Cathleen Mullarkey DesapioPrinceton$183K
- Alan MosesPrinceton$17K
- Angela InzerilloPrinceton$12K
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.